Ceftazidime
* Please be kindly noted products are not for therapeutic use. We do not sell to patients.
| Category | Antibiotics |
| Catalog number | BBF-00743 |
| CAS | 72558-82-8 |
| Molecular Weight | 546.58 |
| Molecular Formula | C22H22N6O7S2 |
| Purity | ≥ 98% |
Online Inquiry
Description
It is produced by the strain of Semisynthetic third generation cephalosporin for injection. Ceftazidime is an antibiotic useful for the treatment of a number of bacterial infections, but it is not used to treat viral infections. It is characterized by having a very strong antibacterial effect on pseudomonas aeruginosa (MIC90 is 4 ㎍/mL).
Specification
| Related CAS | 78439-06-2 (pentahydrate) |
| Synonyms | Fortaz; Tazicef; Fortum; GR20263; GR 20263; GR-20263; Tazidime; Pentacef; Ceptaz; ceftazidima; ceftazidimum; 1-{[(6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(1-carboxy-1-methylethoxy)imino]acetamido]-2-carboxylato-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl}pyridin-1-ium |
| IUPAC Name | (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate |
| Canonical SMILES | CC(C)(C(=O)O)ON=C(C1=CSC(=N1)N)C(=O)NC2C3N(C2=O)C(=C(CS3)C[N+]4=CC=CC=C4)C(=O)[O-] |
| InChI | InChI=1S/C22H22N6O7S2/c1-22(2,20(33)34)35-26-13(12-10-37-21(23)24-12)16(29)25-14-17(30)28-15(19(31)32)11(9-36-18(14)28)8-27-6-4-3-5-7-27/h3-7,10,14,18H,8-9H2,1-2H3,(H4-,23,24,25,29,31,32,33,34)/b26-13-/t14-,18?/m1/s1 |
| InChI Key | ORFOPKXBNMVMKC-MMWTVJBSSA-N |
Properties
| Appearance | White to Yellowish Crystalline Powder |
| Application | Third Generation Cephalosporins |
| Melting Point | 103-113 |
| Solubility | Soluble in Glacial Acetic acid; Slightly soluble in 1% Phosphate buffer; Insoluble in Water, Methanol; Hardly soluble in Acetone, Chloroform |
Reference Reading
1.[TYPING OF VIBRIO CHOLERAE NON O1/NON O139 STRAINS, ISOLATED IN ROSTOV REGION IN 2014].
Selyanskaya NA, Arkhangelskaya IV, Vodopianov AS, Vodopianov SO, Kruglikov VD, Vodyanitskaya SY, Verkina LM, Nepomnyaschaya NB. Zh Mikrobiol Epidemiol Immunobiol. 2016 Jan-Feb;(1):3-9.
AIM: Comparative study of antibiotics resistance and VNTR-typing of Vibrio cholerae non O1/ non O139 strains, isolated on the territory of Rostov region in 2014.
2.The elucidation of mechanisms of ceftazidime resistance among clinical isolates of Pseudomonas aeruginosa using genomic data.
Kos VN1, McLaughlin RE2, Gardner HA3. Antimicrob Agents Chemother. 2016 Apr 11. pii: AAC.03113-15. [Epub ahead of print]
Ceftazidime is one of the few cephalosporins with activity againstPseudomonas aeruginosa Using whole genome comparative analysis, we set out to determine the prevalent mechanism(s) of resistance to ceftazidime using a set of 181 clinical isolates. These isolates represented various multi-locus sequence types that consisted of both ceftazidime susceptible and resistant populations. A presumptive resistance mechanism against ceftazidime was identified in 88% of the non-susceptible isolates using this approach.
3.Investigations on recyclisation and hydrolysis in avibactam mediated serine β-lactamase inhibition.
Choi H1, Paton RS2, Park H3, Schofield CJ2. Org Biomol Chem. 2016 Apr 13. [Epub ahead of print]
β-Lactams inhibit penicillin-binding proteins (PBPs) and serine β-lactamases by acylation of a nucleophilic active site serine. Avibactam is approved for clinical use in combination with ceftazidime, and is a breakthrough non β-lactam β-lactamase inhibitor also reacting via serine acylation. Molecular dynamics (MD) and quantum chemical calculations on avibactam-mediated inhibition of a clinically relevant cephalosporinase reveal that recyclisation of the avibactam derived carbamoyl complex is favoured over hydrolysis. In contrast, we show that analogous recyclisation in β-lactam mediated inhibition is disfavoured. Avibactam recyclisation is promoted by a proton shuttle, a 'structural' water protonating the nucleophilic serine, and stabilization of the negative charge developed on aminocarbonyl oxygen. The results imply the potential of calculations for distinguishing between bifurcating pathways during inhibition and in generating hypotheses for predicting resistance.
4.Comparison of Clinical Laboratory Standards Institute and European Committee on Antimicrobial Susceptibility Testing guidelines for the interpretation of antibiotic susceptibility at a University teaching hospital in Nairobi, Kenya: a cross-sectional stud
Kassim A1, Omuse G2, Premji Z2, Revathi G2. Ann Clin Microbiol Antimicrob. 2016 Apr 11;15(1):21. doi: 10.1186/s12941-016-0135-3.
BACKGROUND: The Clinical Laboratory Standards Institute (CLSI) and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines are the most popular breakpoint guidelines used in antimicrobial susceptibility testing worldwide. The EUCAST guidelines are freely available to users while CLSI is available for non-members as a package of three documents for US $500 annually. This is prohibitive for clinical microbiology laboratories in resource poor settings. We set out to compare antibiotic susceptibility determined by the two guidelines to determine whether adoption of EUCAST guidelines would significantly affect our susceptibility patterns.
Recommended Products
| BBF-03516 | (±)-Naringenin | Inquiry |
| BBF-00969 | Homomycin | Inquiry |
| BBF-01729 | Hygromycin B | Inquiry |
| BBF-00968 | Homoalanosine | Inquiry |
| BBF-05818 | Docosahexaenoic acid | Inquiry |
| BBF-03908 | Miltefosine | Inquiry |
Bio Calculators
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
* Total Molecular Weight:
g/mol
Tip: Chemical formula is case sensitive. C22H30N4O √ c22h30n40 ╳
